We use cookies and similar technologies for analytics, to understand how the site is used. You can accept or decline non-essential cookies. See our Privacy Policy.
Amylyx Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, engages in the discovery and development of treatment options for neurodegenerative diseases and endocrine conditions in the United States. It provides Avexitide, an investigational, first-in-class glucagon-like peptide-1, or GLP-1 receptor antagonist, which is in phase 3 clinical trial to treat post-bariatric hypoglycemia and congenital hyperinsulinism. The company also develops AMX0035, an oral, fixed-dose combination of sodium phenylbutyrate and taurursodiol which is phase 2 clinical trial for the treatment of wolfram syndrome, as well as in phase 2b/3 clinical trial to treat progressive supranuclear palsy; AMX0114, which is in phase 1 clinical trial for the treatment of amyotrophic lateral sclerosis; and long-acting GLP-1 receptor antagonist to treat post-bariatric hypoglycemia and other rare diseases. Further, it develops AMX0318, a GLP-1 receptor antagonist for the treatment of post-bariatric hypoglycemia and other rare diseaees. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.
Amylyx Pharmaceuticals, Inc.는 임상 단계 제약 회사로서, 미국에서 신경퇴행성 질환 및 내분비 질환 치료법의 발굴 및 개발에 주력하고 있습니다. 이 회사는 연구 단계의 계열 내 최초 글루카곤 유사 펩타이드-1, 즉 GLP-1 수용체 길항제인 Avexitide를 보유하고 있으며, 이는 위절제술 후 저혈당증 및 선천성 고인슐린혈증 치료를 위한 3상 임상 시험 단계에 있습니다. 이 회사는 또한 소듐 페닐부티레이트와 타우루르소디올의 경구용 고정 용량 복합제인 AMX0035를 개발하고 있습니다. AMX0035는 울프람 증후군 치료를 위한 2상 임상 시험, 그리고 진행성 핵상 마비 치료를 위한 2b/3상 임상 시험 단계에 있습니다. AMX011